CA3229067A1 - Cyclopentylpyrazole cdk2 inhibitors - Google Patents
Cyclopentylpyrazole cdk2 inhibitors Download PDFInfo
- Publication number
- CA3229067A1 CA3229067A1 CA3229067A CA3229067A CA3229067A1 CA 3229067 A1 CA3229067 A1 CA 3229067A1 CA 3229067 A CA3229067 A CA 3229067A CA 3229067 A CA3229067 A CA 3229067A CA 3229067 A1 CA3229067 A1 CA 3229067A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- jvvv
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252394P | 2021-10-05 | 2021-10-05 | |
| US63/252,394 | 2021-10-05 | ||
| PCT/US2022/077501 WO2023060057A1 (en) | 2021-10-05 | 2022-10-04 | Cyclopentylpyrazole cdk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3229067A1 true CA3229067A1 (en) | 2023-04-13 |
Family
ID=84245758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3229067A Pending CA3229067A1 (en) | 2021-10-05 | 2022-10-04 | Cyclopentylpyrazole cdk2 inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240425478A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412995A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538694A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240077491A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118019734A (cg-RX-API-DMAC7.html) |
| AR (1) | AR127247A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022360968A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229067A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202330501A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023060057A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| WO2023092088A1 (en) * | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
| CA3250419A1 (en) * | 2022-04-28 | 2025-07-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CYCLOPENTANOL ESTER DERIVATIVE SUBSTITUTED BY PYRAZOLE AND ITS USE |
| WO2024104455A1 (zh) * | 2022-11-17 | 2024-05-23 | 山东绿叶制药有限公司 | Cdk2抑制剂及其制备方法和应用 |
| WO2025136671A1 (en) * | 2023-12-20 | 2025-06-26 | Ensem Therapeutics, Inc. | Anilino-pyrazole derivatives, compositions and methods thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3128155C (en) * | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
| CN113766125B (zh) | 2019-09-29 | 2022-10-25 | Oppo广东移动通信有限公司 | 对焦方法和装置、电子设备、计算机可读存储介质 |
| MX2023009086A (es) * | 2021-02-12 | 2023-08-08 | Relay Therapeutics Inc | Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos. |
-
2022
- 2022-10-04 KR KR1020247011084A patent/KR20240077491A/ko active Pending
- 2022-10-04 JP JP2024520826A patent/JP2024538694A/ja active Pending
- 2022-10-04 CA CA3229067A patent/CA3229067A1/en active Pending
- 2022-10-04 TW TW111137712A patent/TW202330501A/zh unknown
- 2022-10-04 WO PCT/US2022/077501 patent/WO2023060057A1/en not_active Ceased
- 2022-10-04 CN CN202280065852.1A patent/CN118019734A/zh active Pending
- 2022-10-04 US US18/698,664 patent/US20240425478A1/en active Pending
- 2022-10-04 AU AU2022360968A patent/AU2022360968A1/en active Pending
- 2022-10-04 AR ARP220102682A patent/AR127247A1/es unknown
- 2022-10-04 EP EP22800510.4A patent/EP4412995A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240077491A (ko) | 2024-05-31 |
| AU2022360968A1 (en) | 2024-02-29 |
| EP4412995A1 (en) | 2024-08-14 |
| AR127247A1 (es) | 2024-01-03 |
| WO2023060057A1 (en) | 2023-04-13 |
| CN118019734A (zh) | 2024-05-10 |
| JP2024538694A (ja) | 2024-10-23 |
| US20240425478A1 (en) | 2024-12-26 |
| TW202330501A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3221390A1 (en) | Sulfur-containing heteroaromatic tricyclic kras inhibitors | |
| CA3063596C (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| EP4412995A1 (en) | Cyclopentylpyrazole cdk2 inhibitors | |
| WO2024040080A1 (en) | Kras inhibitor conjugates | |
| KR102589213B1 (ko) | 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제 | |
| CA3150738A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| JP2017530985A (ja) | Wntシグナル経路阻害剤としてのN‐ピリジニルアセトアミド誘導体 | |
| CN113508115A (zh) | 吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病 | |
| JP2020526557A (ja) | ムスカリン性アセチルコリン受容体m4のアンタゴニスト | |
| AU2020355837B2 (en) | AZA-quinoline compounds and uses thereof | |
| CA3178450A1 (en) | Amide compounds and uses thereof | |
| JP2019524678A (ja) | ヘッジホッグ経路アンタゴニスト活性を持つキラル複素環式化合物、及びその製造方法、並びに応用 | |
| TWI835476B (zh) | 哌嗪吲唑糖皮質素受體拮抗劑 | |
| US12234232B2 (en) | Aromatic heterocyclic compound with kinase inhibitory activity | |
| CN107428762A (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
| CA3104927A1 (en) | Tricyclic compounds | |
| IL301275A (en) | Heterocyclic heteroaryl compounds and their uses | |
| JP2019518032A (ja) | Pi3k beta阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体 | |
| HK40110722A (en) | Cyclopentylpyrazole cdk2 inhibitors | |
| CN116323582B (zh) | 杂芳环类化合物及其用途 | |
| EA050799B1 (ru) | Гетероарильные гетероциклические соединения и их применение | |
| IL296700A (en) | Process, compositions, and crystalline of substituted pyridinone-pyridinyl compounds | |
| HK40034453B (en) | Pyrimidine cyclohexenyl glucocorticoid receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240923 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250923 |